FASTinov will be at the ECCMID congress

The company has started the commercialization of its ultra-rapid Antibiotic Susceptibility Testing technology that delivers antibiograms in less than two hours directly from blood cultures. This technology will feature amongst the prominent novelties of this event, because it allows for the first time the elivery of an intibiogram indicating to which antibiotics the infectious microbial agent is susceptible to, a critical decision in the management of critically infected patients.

“ECCMID is the largest Clinical Microbiology & Infectious Diseases events in the world, and thousands of experts present their latest findings and learn about the scientific and technological breakthroughs”
said Ricardo Sousa, who leads FASTinov’s commercial operations.

“This will be a great opportunity to present our breakthrough AST technology to experts from all over the world”.

For more information and the opportunity to present its ultra-rapid AST technology, FAStinov will be present at the upcoming 32nd European Congress of Clinical Microbiology & Infectious Diseases, ECCMID, in Lisbon, Portugal.

About FASTinov
FASTinov has developed ultra-rapid, phenotypic antibiotic susceptibility tests for bloodstream infections that deliver antibiograms in less than 2 hours, based upon patented technologies. The company is based in Porto, Portugal.

• For press inquiries, please contact: info@fastinov.com